Fragment 176-191 & Mod GRF 1-29 & Ipamorelin Blend
A research blend combining Fragment 176-191 with Mod GRF 1-29 and ipamorelin — identical in design to the CJC-1295 + Ipamorelin + Fragment blend but labeled under the Mod GRF 1-29 nomenclature.
Community Rating
No ratings yet
⚠ Research & Educational Use Only. Fragment 176-191 & Mod GRF 1-29 & Ipamorelin Blend is a research chemical documented here for scientific education. All information references peer-reviewed literature and preclinical/clinical study data. Not for human consumption. Not medical advice. Consult a licensed researcher or healthcare professional before any laboratory use.
- Same design as Fragment 176-191 + CJC-1295 + Ipamorelin
- Selective lipolysis + GH axis stimulation
- Combined fat loss + lean mass support
- Fragment 176-191 & Mod GRF 1-29 & Ipamorelin Blend is not FDA-approved for human use. It is a research chemical for scientific study only.
Research At a Glance
- Same design as Fragment 176-191 + CJC-1295 + Ipamorelin
- Selective lipolysis + GH axis stimulation
- Combined fat loss + lean mass support
- Physiological GH pulsatility preserved
What is Fragment 176-191 & Mod GRF 1-29 & Ipamorelin Blend?
Tap any underlined term for an instant definition.
Fragment 176-191 & Mod GRF 1-29 & Ipamorelin Blend is functionally identical to the Fragment 176-191 + CJC-1295 + Ipamorelin blend. The naming difference reflects that CJC-1295 (without DAC) and Mod GRF 1-29 are the same compound; researchers and suppliers sometimes use one name, sometimes the other.
What It Is
- Same three-component design: Fragment 176-191 (selective lipolysis) + Mod GRF 1-29 / CJC-1295 no DAC (GHRHR) + Ipamorelin (GHS-R1a)
- Mechanism, expected outcomes, and dosing identical to Fragment 176-191 + CJC-1295 + Ipamorelin blend
Mechanism
- Fragment 176-191: beta-adrenergic receptor-like agonism on adipocytes; reduces fat mass without affecting IGF-1
- Mod GRF 1-29 + Ipamorelin: synergistic GHRHR + GHS-R1a stimulation producing 3-4x GH pulses vs either alone
Dosing From the Literature
- Fragment 176-191: 200-500 mcg subcutaneous, morning fasted
- Mod GRF 1-29: 100-200 mcg per injection
- Ipamorelin: 200-300 mcg per injection
- Combined in single administration
Storage and Handling
- Lyophilised: 2-8 degrees C; 24 months
- Reconstituted: 2-8 degrees C; use within 21 days
Key Research Benefits
Documented effects observed in preclinical and clinical studies on Fragment 176-191 & Mod GRF 1-29 & Ipamorelin Blend. See all Peptide Blends peptides for comparison.
Side Effects & Risks
Adverse effects reported in the research literature. All data sourced from preclinical and clinical study reports. View all peptides' side effects →
Dosing Data from the Literature
Doses referenced below are sourced from published preclinical and clinical studies. Use the peptide dose calculator to convert these values to injection volume.
Administration in Research Settings
Standard reconstitution and administration methodology for laboratory research use.
Subcutaneous injection. Administer fasted in the morning for optimal fat mobilization.
Explore Further
Quick Reference
More in Peptide Blends
- Sermorelin & Ipamorelin Blend
- Sermorelin & GHRP-2 Blend
- Sermorelin & GHRP-6 Blend
- Sermorelin & GHRP-6 & GHRP-2 Triple Blend
Research Use Only
This information is for educational research purposes only. This is not medical advice. Consult a qualified healthcare professional.